BRPI0817881A2 - Compostos orgânicos e seus usos - Google Patents

Compostos orgânicos e seus usos

Info

Publication number: BRPI0817881A2
Authority: BR; Brazil
Prior art keywords: organic compounds; compounds; organic
Prior art date: 2007-10-10

Application number

Other languages

English (en)

Inventor

Shawn D Britt

Lech Ciszewsky

Jiping Fu

Subramanian Karur

Yugang Liu

David Thomas Parker

Mahavir Prashad

Prakash Raman

Mohindra Seepersaud

Rui Zheng

Peichao Lu

Pascal Rigollier

Aregahegn Yifru

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-10

Filing date

2008-10-08

Publication date

2015-03-31

2008-10-08 Application filed by Novartis Ag filed Critical Novartis Ag

2015-03-31 Publication of BRPI0817881A2 publication Critical patent/BRPI0817881A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

BRPI0817881 2007-10-10 2008-10-08 Compostos orgânicos e seus usos BRPI0817881A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97897407P	2007-10-10	2007-10-10
PCT/EP2008/063460 WO2009047264A1 (en)	2007-10-10	2008-10-08	Spiropyrrolidines and their use against hcv and hiv infection

Publications (1)

Publication Number	Publication Date
BRPI0817881A2 true BRPI0817881A2 (pt)	2015-03-31

Family

ID=40243948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817881 BRPI0817881A2 (pt)	2007-10-10	2008-10-08	Compostos orgânicos e seus usos

Country Status (20)

Country	Link
US (2)	US8008263B2 (pt)
EP (1)	EP2205584A1 (pt)
JP (1)	JP5095824B2 (pt)
KR (2)	KR101396696B1 (pt)
CN (2)	CN104016970A (pt)
AR (1)	AR068756A1 (pt)
AU (1)	AU2008309589B2 (pt)
BR (1)	BRPI0817881A2 (pt)
CA (1)	CA2702132A1 (pt)
CL (1)	CL2008002995A1 (pt)
CO (1)	CO6270317A2 (pt)
CR (1)	CR11310A (pt)
EA (1)	EA020951B1 (pt)
MA (1)	MA31767B1 (pt)
MX (1)	MX2010003916A (pt)
PE (1)	PE20091237A1 (pt)
TN (1)	TN2010000137A1 (pt)
TW (1)	TW200932737A (pt)
WO (1)	WO2009047264A1 (pt)
ZA (1)	ZA201001585B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7825152B2 (en) *	2006-04-11	2010-11-02	Novartis Ag	Organic compounds and their uses
US8293705B2 (en)	2007-12-21	2012-10-23	Avila Therapeutics, Inc.	HCV protease inhibitors and uses thereof
KR20150117305A (ko)	2007-12-21	2015-10-19	셀진 아빌로믹스 리서치, 인코포레이티드	Ｈｃｖ 프로테아제 억제제 및 이의 용도
WO2009082701A1 (en)	2007-12-21	2009-07-02	Avila Therapeutics, Inc.	Hcv protease inhibitors and uses thereof
US8309685B2 (en)	2007-12-21	2012-11-13	Celgene Avilomics Research, Inc.	HCV protease inhibitors and uses thereof
KR20110075019A (ko) *	2008-10-15	2011-07-05	인터뮨, 인크.	치료용 항바이러스성 펩티드
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) *	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
CA2775697A1 (en) *	2009-09-28	2011-03-31	Intermune, Inc.	Cyclic peptide inhibitors of hepatitis c virus replication
WO2011041551A1 (en) *	2009-10-01	2011-04-07	Intermune, Inc.	Therapeutic antiviral peptides
CA2811799A1 (en) *	2010-10-08	2012-04-12	Novartis Ag	Vitamin e formulations of sulfamide ns3 inhibitors
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2013030750A1 (en)	2011-09-01	2013-03-07	Lupin Limited	Antiviral compounds
CA2862755A1 (en)	2012-02-10	2013-08-15	Lupin Limited	Antiviral compounds with a dibenzooxaheterocycle moiety
CN103420991B (zh) *	2012-05-17	2017-07-07	乳源东阳光药业有限公司	作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TW201408669A (zh) *	2012-08-08	2014-03-01	Merck Sharp & Dohme	Ｈｃｖｎｓ３蛋白酶抑制劑
TW201412709A (zh) *	2012-09-28	2014-04-01	Sunshine Lake Pharma Co Ltd	作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
SI2909205T1 (sl)	2012-10-19	2017-02-28	Bristol-Myers Squibb Company	9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
US9334279B2 (en)	2012-11-02	2016-05-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2014070974A1 (en)	2012-11-05	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014082379A1 (en) *	2012-11-29	2014-06-05	Sunshine Lake Pharma Co.,Ltd.	Spiro ring compound as hepatitis c virus (hcv) inhibitor and uses thereof field of the invention
WO2014082381A1 (en) *	2012-11-29	2014-06-05	Sunshine Lake Pharma Co., Ltd.	Spiro ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof
US9802949B2 (en)	2012-11-29	2017-10-31	Sunshine Lake Pharma Co., Ltd.	Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
US9580463B2 (en)	2013-03-07	2017-02-28	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TR201911139T4 (tr)	2013-03-15	2019-08-21	Zymeworks Inc	Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri.
AU2014373640B2 (en)	2013-12-27	2018-08-30	Var2 Pharmaceuticals Aps	VAR2CSA-drug conjugates
EP3086815B1 (en)	2013-12-27	2022-02-09	Zymeworks Inc.	Sulfonamide-containing linkage systems for drug conjugates
US9738629B2 (en)	2014-01-23	2017-08-22	Sunshine Lake Pharma Co., Ltd.	Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
SG11201702143PA (en)	2014-09-17	2017-04-27	Zymeworks Inc	Cytotoxic and anti-mitotic compounds, and methods of using the same
CN111433210A (zh)	2017-12-20	2020-07-17	诺华股份有限公司	作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
US11976084B2 (en)	2020-11-23	2024-05-07	Enanta Pharmaceuticals, Inc.	Spiropyrrolidine derived antiviral agents
WO2022140515A1 (en) *	2020-12-22	2022-06-30	The Regents Of The University Of California	Novel cyp3a4-specific inhibitors and methods of using same
WO2022235605A1 (en)	2021-05-04	2022-11-10	Enanta Pharmaceuticals, Inc.	Novel macrocyclic antiviral agents
US12398147B2 (en)	2021-05-11	2025-08-26	Enanta Pharmaceuticals, Inc.	Macrocyclic spiropyrrolidine derived antiviral agents
WO2023003610A1 (en) *	2021-07-23	2023-01-26	Enanta Pharmaceuticals, Inc.	Novel spiropyrrolidine derived antiviral agents
US12479854B2 (en)	2021-07-29	2025-11-25	Enanta Pharmaceuticals, Inc.	Spiropyrrolidine derived antiviral agents
US11919910B2 (en)	2021-11-12	2024-03-05	Enanta Pharmaceuticals, Inc.	Spiropyrrolidine derived antiviral agents
US11858945B2 (en)	2021-11-12	2024-01-02	Enanta Pharmaceuticals, Inc.	Alkyne-containing antiviral agents
US11912714B2 (en)	2021-11-12	2024-02-27	Enanta Pharmaceuticals, Inc.	Spiropyrrolidine derived antiviral agents
WO2023107417A1 (en)	2021-12-08	2023-06-15	Enanta Pharmaceuticals, Inc.	Heterocyclic antiviral agents
US11993600B2 (en)	2021-12-08	2024-05-28	Enanta Pharmaceuticals, Inc.	Saturated spirocyclics as antiviral agents
WO2023196307A1 (en)	2022-04-05	2023-10-12	Enanta Pharmaceuticals, Inc.	Novel spiropyrrolidine derived antiviral agents

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL153670A0 (en) *	2000-07-21	2003-07-06	Schering Corp	Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) *	2000-07-21	2007-07-17	Schering Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) *	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA04007163A (es) *	2002-01-23	2004-10-29	Schering Corp	Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c.
JP4825129B2 (ja) *	2003-06-17	2011-11-30	シェーリングコーポレイション	（１ｒ，２ｓ，５ｓ）−６，６−ジメチル−３−アザビシクロ［３，１，０］ヘキサン−２−カルボキシレートまたはその塩の調製のためのプロセスおよび中間体
JP4527722B2 (ja) *	2003-08-26	2010-08-18	シェーリングコーポレイション	Ｃ型肝炎ウイルスの新規のペプチド模倣性ｎｓ３−セリンプロテアーゼインヒビター
MY148123A (en) *	2003-09-05	2013-02-28	Vertex Pharma	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2004274468B2 (en) *	2003-09-18	2009-07-23	Vertex Pharmaceuticals, Incorporated	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20060003942A1 (en) *	2003-10-27	2006-01-05	Roger Tung	Combinations for HCV treatment
CN100509784C (zh) *	2003-12-11	2009-07-08	先灵公司	丙型肝炎病毒ns3/ns4a丝氨酸蛋白酶的抑制剂
EP1711515A2 (en) *	2004-02-04	2006-10-18	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DK1730110T3 (da) *	2004-02-27	2010-09-27	Schering Corp	Svovlforbindelser som inhibitorer af hepatitis C-virus NS3-serinprotease
US7635694B2 (en) *	2004-02-27	2009-12-22	Schering Corporation	Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
TW200529822A (en) *	2004-02-27	2005-09-16	Schering Corp	Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
CN1950393A (zh) *	2004-02-27	2007-04-18	先灵公司	丙型肝炎病毒ns3蛋白酶的抑制剂
EP1737821B1 (en) *	2004-02-27	2009-08-05	Schering Corporation	3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
TW200602037A (en) *	2004-02-27	2006-01-16	Schering Corp	Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
PE20060309A1 (es) *	2004-05-06	2006-04-13	Schering Corp	(1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
ZA200700030B (en) *	2004-06-08	2009-06-24	Vertex Pharma	Pharmaceutical compositions
JP2008511633A (ja) *	2004-08-27	2008-04-17	シェーリングコーポレイション	Ｃ型肝炎ウィルスｎｓ３セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物
WO2006034337A2 (en) *	2004-09-23	2006-03-30	Wyeth	Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus
TW201300108A (zh) *	2004-10-01	2013-01-01	Vertex Pharma	Ｃ型肝炎病毒（ｈｃｖ）ｎｓ３-ｎｓ４ａ蛋白酶抑制劑
TWI437990B (zh) *	2004-10-29	2014-05-21	Vertex Pharma	Vx-950之醫藥用途
US20060281689A1 (en) *	2005-06-02	2006-12-14	Schering Corporation	Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20070021351A1 (en) *	2005-06-02	2007-01-25	Schering Corporation	Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
WO2006130686A2 (en) *	2005-06-02	2006-12-07	Schering Corporation	Hcv protease inhibitors in combination with food
US20070004635A1 (en) *	2005-06-02	2007-01-04	Schering Corporation	Method of treating interferon non-responders using HCV protease inhibitor
WO2006130666A2 (en) *	2005-06-02	2006-12-07	Schering Corporation	Medicaments and methods combining a hcv protease inhibitor and an akr competitor
US7608592B2 (en) *	2005-06-30	2009-10-27	Virobay, Inc.	HCV inhibitors
AU2006275413B2 (en) *	2005-08-02	2012-07-19	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases
AR055395A1 (es) *	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
AU2007238252A1 (en) *	2006-04-11	2007-10-25	Novartis Ag	HCV inhibitors comprising beta amino acids and their uses
US7825152B2 (en) *	2006-04-11	2010-11-02	Novartis Ag	Organic compounds and their uses
WO2007120595A2 (en) *	2006-04-11	2007-10-25	Novartis Ag	Amines for the treatment of hcv
CN101421292A (zh) *	2006-04-11	2009-04-29	诺瓦提斯公司	Hcv抑制剂
WO2008059367A1 (en)	2006-11-14	2008-05-22	Pfizer Products Inc.	Penem prodrugs
CL2008000017A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
AR064735A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
US20090163508A1 (en)	2007-10-10	2009-06-25	Takeda Pharmaceutical Company Limited	Amide compound
UA100527C2 (en)	2007-10-10	2013-01-10	Астразенека Аб	Benzothiazoles as ghrelin receptor modulators
US8030354B2 (en)	2007-10-10	2011-10-04	Amgen Inc.	Substituted biphenyl GPR40 modulators

2008
- 2008-10-08 CA CA2702132A patent/CA2702132A1/en not_active Abandoned
- 2008-10-08 EP EP08805142A patent/EP2205584A1/en not_active Withdrawn
- 2008-10-08 AR ARP080104396A patent/AR068756A1/es not_active Application Discontinuation
- 2008-10-08 BR BRPI0817881 patent/BRPI0817881A2/pt not_active IP Right Cessation
- 2008-10-08 WO PCT/EP2008/063460 patent/WO2009047264A1/en not_active Ceased
- 2008-10-08 KR KR1020127015695A patent/KR101396696B1/ko not_active Expired - Fee Related
- 2008-10-08 AU AU2008309589A patent/AU2008309589B2/en not_active Ceased
- 2008-10-08 CN CN201410273335.0A patent/CN104016970A/zh active Pending
- 2008-10-08 CN CN200880110944.7A patent/CN101868452B/zh not_active Expired - Fee Related
- 2008-10-08 EA EA201000556A patent/EA020951B1/ru not_active IP Right Cessation
- 2008-10-08 JP JP2010528385A patent/JP5095824B2/ja not_active Expired - Fee Related
- 2008-10-08 MX MX2010003916A patent/MX2010003916A/es active IP Right Grant
- 2008-10-08 KR KR1020107007789A patent/KR101218882B1/ko not_active Expired - Fee Related
- 2008-10-09 CL CL2008002995A patent/CL2008002995A1/es unknown
- 2008-10-09 PE PE2008001744A patent/PE20091237A1/es not_active Application Discontinuation
- 2008-10-09 TW TW097139071A patent/TW200932737A/zh unknown
- 2008-10-10 US US12/249,186 patent/US8008263B2/en not_active Expired - Fee Related
2010
- 2010-03-04 ZA ZA2010/01585A patent/ZA201001585B/en unknown
- 2010-03-11 CR CR11310A patent/CR11310A/es not_active Application Discontinuation
- 2010-03-26 TN TNP2010000137A patent/TN2010000137A1/fr unknown
- 2010-04-08 MA MA32757A patent/MA31767B1/fr unknown
- 2010-04-30 CO CO10051497A patent/CO6270317A2/es not_active Application Discontinuation
2011
- 2011-07-19 US US13/185,683 patent/US8222425B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2008309589B2 (en)	2012-07-05
US20090137495A1 (en)	2009-05-28
JP5095824B2 (ja)	2012-12-12
CN101868452B (zh)	2014-08-06
JP2011500528A (ja)	2011-01-06
CN101868452A (zh)	2010-10-20
CN104016970A (zh)	2014-09-03
CA2702132A1 (en)	2009-04-16
ZA201001585B (en)	2010-12-29
AU2008309589A1 (en)	2009-04-16
CO6270317A2 (es)	2011-04-20
KR101218882B1 (ko)	2013-01-07
TN2010000137A1 (en)	2011-09-26
KR20100051749A (ko)	2010-05-17
WO2009047264A1 (en)	2009-04-16
US8222425B2 (en)	2012-07-17
CR11310A (es)	2010-05-06
US20110275819A1 (en)	2011-11-10
MA31767B1 (fr)	2010-10-01
KR101396696B1 (ko)	2014-05-16
US8008263B2 (en)	2011-08-30
TW200932737A (en)	2009-08-01
AR068756A1 (es)	2009-12-02
EA020951B1 (ru)	2015-03-31
KR20120094049A (ko)	2012-08-23
EP2205584A1 (en)	2010-07-14
PE20091237A1 (es)	2009-09-14
EA201000556A1 (ru)	2010-10-29
MX2010003916A (es)	2010-05-05
CL2008002995A1 (es)	2009-06-26

Publication	Publication Date	Title
BRPI0817881A2 (pt)	2015-03-31	Compostos orgânicos e seus usos
BRPI0710878A2 (pt)	2015-03-31	Compostos orgânicos e seus usos
BRPI0813244A2 (pt)	2014-12-23	Compostos e seus usos 708
BRPI1016150A2 (pt)	2016-04-19	compostos heterocíclicos e seus usos.
BRPI0908853A2 (pt)	2017-05-30	composto oligopeptídicos e seus usos
SMAP200900082A (it)	2009-11-06	Composti organici e loro utilizzazione
BRPI0910746A2 (pt)	2016-07-26	reticuladores e seus usos
BRPI0921862A2 (pt)	2015-12-29	inibidores de raf e seus usos
BR112012000660A2 (pt)	2016-11-16	compostos heterociclos e seus usos
BRPI0718182A2 (pt)	2014-02-25	Oligorribonucleotídeos e seus usos.
DK2240490T3 (da)	2013-12-16	Organiske forbindelser
BRPI0817434A2 (pt)	2015-06-16	Composto orgânicos
BRPI0811562A2 (pt)	2014-12-09	Compostos orgânicos
BRPI0909185A2 (pt)	2015-08-25	Derivado de vitamina e e seus usos
DK2361116T3 (da)	2019-05-20	Bestrålingsindretning
BRPI0913640A2 (pt)	2016-08-16	substâncias policrômicas e seus usos
BRPI0913885A2 (pt)	2015-08-25	Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI0814314A2 (pt)	2015-05-26	Microbiocidas
BRPI0814629A2 (pt)	2015-01-27	Compostos e seus efeitos sobre o comportamento alimentar
BRPI0821401A2 (pt)	2014-10-14	Compostos orgânicos
BRPI0818005A2 (pt)	2015-04-14	Compostos orgânicos
DE502008001632D1 (de)	2010-12-09	Karosserieaufbau
BRPI0808846A2 (pt)	2019-09-24	fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
BRPI0820745A2 (pt)	2015-06-16	Compostos orgânicos
BRPI0813739A2 (pt)	2019-09-24	compostos orgânicos

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.